Bristol-Myers’ Big Bet On Hepatitis C Crashes
09:06 EDT 2 Aug 2012 | Pharmalot
Earlier this year, Bristol-Myers Squibb agreed to pay $2.5 billion in cash for Inhibitex, which at the time had completed only Phase I testing for a hepatitis C compound. Although expensive, the rationale was that hepatitis C is the next huge market..
Original Article: Bristol-Myers’ Big Bet On Hepatitis C Crashes
More From BioPortfolio on "Bristol-Myers’ Big Bet On Hepatitis C Crashes"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
